COX inhibitors and breast cancer.
COX inhibitors and breast cancer.
复制标题
DOI：
10.1038/sj.bjc.6602942
复制
发表时间：
2006-02-13
影响因子：
8.8
通讯作者：
Waxman, J
中科院分区：
文献类型：
--
作者：
Mazhar, D;Ang, R;Waxman, J
有相当多的证据表明，前列腺素在癌症的发展和生长中发挥着重要作用。环氧合酶(COX)催化花生四烯酸转化为前列腺素。近年来，环氧合酶抑制剂在预防和治疗恶性肿瘤中的可能作用引起了人们的兴趣。环氧合酶-2(COX-2)在包括乳腺癌在内的几种上皮性肿瘤中过表达。临床前证据支持COX抑制剂在乳腺癌中的抗肿瘤作用。然而，这种关联的流行病学证据是相互矛盾的。正在进行试验，以研究COX抑制剂在乳腺癌的化学预防以及新辅助、辅助和转移治疗环境中的单独使用和与其他药物的联合使用。在评估这些药物的潜在用途时，特别是在癌症化学预防方面，安全性概况与它们的有效性一样重要。最近，人们对选择性和非选择性COX-抑制剂的心血管安全性的担忧都得到了强调。
There is considerable evidence to suggest that prostaglandins play an important role in the development and growth of cancer. The enzyme cyclo-oxygenase (COX) catalyses the conversion of arachidonic acid to prostaglandins. In recent years, there has been interest in a possible role for COX inhibitors in the prevention and treatment of malignancy. Cyclo-oxygenase-2 (COX-2) is overexpressed in several epithelial tumours, including breast cancer. Preclinical evidence favours an antitumour role for COX inhibitors in breast cancer. However, the epidemiological evidence for an association is conflicting. Trials are being conducted to study the use of COX inhibitors alone and in combination with other agents in the chemoprevention of breast cancer, and in the neo-adjuvant, adjuvant, and metastatic treatment settings. In evaluating the potential use of these agents particularly in cancer chemoprophylaxis, the safety profile is as important as their efficacy. Concern over the cardiovascular safety of both selective and nonselective COX-inhibitors has recently been highlighted.
登录
查看更多内容
影响因子：
8.8
作者：
通讯作者：
--
COX-2表达与原位导管癌中的侵袭性表型有关。
影响因子：
8.8
作者：
Boland, G P;Butt, I S;Prasad, R;Knox, W F;Bundred, N J
通讯作者：
Bundred, N J
影响因子：
13.6
作者：
BENNETT, A
通讯作者：
BENNETT, A
DOI：
10.1093/jnci/90.6.455
发表时间：
1998-03-18
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Hwang, D;Scollard, D;Levine, E
通讯作者：
Levine, E
影响因子：
5.1
作者：
Coogan, PF;Rao, RS;Shapiro, S
通讯作者：
Shapiro, S